Vaccines Articles
The Centers for Disease Control and Prevention has issues its recommendations for use of the seasonal 2026-2027 influenza (flu) vaccines.
Updated COVID-19 vaccines from Moderna, Novavax-Sanofi and Pfizer-BioNTech have been approved by the U.S. Food and Drug Administration.
A Phase III trial evaluating adjuvant treatment with intismeran autogene in combination with KEYTRUDA (pembrolizumab) showed positive results in treating patients with completely resected stage IIB-IV melanoma.
The U.S. Food and Drug Administration has approved mFLUSIVA (mRNA-1010), a new vaccine against seasonal influenza, for use in all adults 50 years and older.
Researchers have developed an experimental therapeutic nasal DNA vaccine for tuberculosis.
Scientists have developed a new HIV vaccine that has the potential to protect humans from developing HIV infection and AIDS.
The Bacillus Calmette-Guérin accine may alter immune activity around the brain and change levels of a protein closely associated with Alzheimer’s disease in older adults without evidence of the condition.
A UTHealth study found adults 65 and older had a lower risk of developing Alzheimer’s disease after receiving a high-dose flu vaccine.
The Statens Serum Institut in Copenhagen found that flu vaccines may protect against heart attack and stroke, even if the flu is still developed after vaccination.
The U.S. Food and Drug Administration’s accines and Related Biological Products Advisory Committee voted to recommend approval of the Moderna’s investigational mRNA influenza vaccine, which will be marketed under the brand name mFlusiva, for the prevention of flu in adults age 50 to 64.
ccording to three different studies, COVID-19 vaccines were associated with a lower risk of major adverse cardiovascular events (MACE), in addition to other outcomes, particularly among older adults.